FDA
-
-
-
-
-
-
-
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Truist Securities models $730M peak revenue for Protagonist Therapeutics (PTGX) in Icotyde royalties
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $117 at H.C. Wainwright
-
-
-
-
-
-
-
Jefferies says this stock offers favorable setup with further upside potential
-
-
-
-
-
-
-
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide in Polycythemia Vera Selected for Oral Presentations at the ASH 2021 Annual Meeting
-
327,780 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

